Is Johnson & Johnson an Underdog in the COVID-19 Vaccine Race?

You won't have a very difficult time identifying ways that Johnson & Johnson (NYSE: JNJ) is a leader. It's the largest healthcare company in the world with a market cap of close to $400 billion. J&J ranks near the top of three different healthcare segments -- pharmaceuticals, medical devices, and consumer health. 

Johnson & Johnson announced in March that it would invest more than $1 billion to develop a COVID-19 vaccine candidate. That amount is greater than the market caps earlier this year of some drugmakers that set out to develop novel coronavirus vaccines. But could giant Johnson & Johnson actually be an underdog in the COVID-19 vaccine race? 

Image source: Getty Images.

Continue reading

Source Fool.com